FerranniniECushmanWC. Diabetes and hypertension: The bad companions. Lancet2012; 380: 601–610.
2.
SeraFJinZRussoC, et al.Relationship of office and ambulatory blood pressure with left ventricular global longitudinal strain. Am J Hypertens2016; 29: 1261–1267.
3.
RussoCJinZElkindMS, et al.Prevalence and prognostic value of subclinical left ventricular systolic dysfunction by global longitudinal strain in a community-based cohort. Eur J Heart Fail2014; 16: 1301–1309.
4.
Soufi Taleb BendiabNMeziane-TaniAOuabdesselamS, et al.Factors associated with global longitudinal strain decline in hypertensive patients with normal left ventricular ejection fraction. Eur J Prev Cardiol2017; 24: 1463–1472.
5.
WangQGaoYTanK, et al.Assessment of left ventricular function by three-dimensional speckle-tracking echocardiography in well-treated type 2 diabetes patients with or without hypertension. J Clin Ultrasound2015; 43: 502–511.
6.
FerranniniEBuzzigoliGBonadonnaR, et al.Insulin resistance in essential hypertension. N Engl J Med1987; 317: 350–357.
7.
ChanJHanekomLWongC, et al.Differentiation of subendocardial and transmural infarction using two-dimensional strain rate imaging to assess short-axis and long-axis myocardial function. J Am Coll Cardiol2006; 48: 2026–2033.
8.
ErnandeLBergerotCRietzschelER, et al.Diastolic dysfunction in patients with type 2 diabetes mellitus: Is it really the first marker of diabetic cardiomyopathy?J Am Soc Echocardiogr2011; 24: 1268–1275.e1.
9.
AldermanMH. New onset diabetes during antihypertensive therapy. Am J Hypertens2008; 21: 493–499.
10.
RizzoMNikolicDPattiAM, et al.GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms. Biochim Biophys Acta Mol Basis Dis2018; 1864: 2814–2821.
